更正“Spesolimab：皮肤病学抗il -36受体抗体的综合综述”。

IF 3.5 4区医学 Q1 DERMATOLOGY

International Journal of Dermatology Pub Date : 2025-04-09 DOI:10.1111/ijd.17788

引用次数: 0

摘要

P. Vijayasankar, GopinathH,没吃。Radhakrishnan A.B。年代,Karthikeyan。K.《Spesolimab：皮肤病学中抗il -36受体抗体的综合综述》中华皮肤科杂志，2009;32(1):391 - 391。doi: 10.1111 / ijd.16941。选择题部分第5题的正确答案是c，我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to “Spesolimab: A Comprehensive Review on the Anti-IL-36 Receptor Antibody in Dermatology”

P. Vijayasankar, Gopinath. H, Murthy. A.B, Radhakrishnan. S, Karthikeyan. K. “Spesolimab: a comprehensive review on the anti-IL-36 receptor antibody in dermatology.” Int J Dermatol. 2024;63(1): 88–93. doi: 10.1111/ijd.16941.

The accurate answer to question number 5 in the Multiple Choice Questions section is C.

We apologize for this error.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Dermatology 医学-皮肤病学

CiteScore

4.70

自引率

2.80%

发文量

476

审稿时长

3 months

期刊介绍： Published monthly, the International Journal of Dermatology is specifically designed to provide dermatologists around the world with a regular, up-to-date source of information on all aspects of the diagnosis and management of skin diseases. Accepted articles regularly cover clinical trials; education; morphology; pharmacology and therapeutics; case reports, and reviews. Additional features include tropical medical reports, news, correspondence, proceedings and transactions, and education. The International Journal of Dermatology is guided by a distinguished, international editorial board and emphasizes a global approach to continuing medical education for physicians and other providers of health care with a specific interest in problems relating to the skin.